收费全文 | 2254732篇 |
免费 | 177462篇 |
国内免费 | 4052篇 |
耳鼻咽喉 | 31718篇 |
儿科学 | 74740篇 |
妇产科学 | 64726篇 |
基础医学 | 319285篇 |
口腔科学 | 65630篇 |
临床医学 | 196360篇 |
内科学 | 441865篇 |
皮肤病学 | 48480篇 |
神经病学 | 181860篇 |
特种医学 | 90864篇 |
外国民族医学 | 767篇 |
外科学 | 347486篇 |
综合类 | 54365篇 |
现状与发展 | 3篇 |
一般理论 | 768篇 |
预防医学 | 171982篇 |
眼科学 | 52405篇 |
药学 | 168351篇 |
2篇 | |
中国医学 | 4160篇 |
肿瘤学 | 120429篇 |
2018年 | 21551篇 |
2016年 | 18690篇 |
2015年 | 21537篇 |
2014年 | 30015篇 |
2013年 | 46159篇 |
2012年 | 62186篇 |
2011年 | 65720篇 |
2010年 | 39087篇 |
2009年 | 37430篇 |
2008年 | 62937篇 |
2007年 | 66580篇 |
2006年 | 67464篇 |
2005年 | 65683篇 |
2004年 | 64329篇 |
2003年 | 61578篇 |
2002年 | 60409篇 |
2001年 | 103990篇 |
2000年 | 107437篇 |
1999年 | 90941篇 |
1998年 | 23698篇 |
1997年 | 21506篇 |
1996年 | 21288篇 |
1995年 | 21914篇 |
1994年 | 20636篇 |
1993年 | 19577篇 |
1992年 | 74745篇 |
1991年 | 72449篇 |
1990年 | 70803篇 |
1989年 | 68583篇 |
1988年 | 63699篇 |
1987年 | 62832篇 |
1986年 | 60029篇 |
1985年 | 57701篇 |
1984年 | 43273篇 |
1983年 | 37026篇 |
1982年 | 21905篇 |
1981年 | 19424篇 |
1980年 | 18338篇 |
1979年 | 40809篇 |
1978年 | 28459篇 |
1977年 | 23916篇 |
1976年 | 22602篇 |
1975年 | 24228篇 |
1974年 | 29490篇 |
1973年 | 28362篇 |
1972年 | 26260篇 |
1971年 | 24585篇 |
1970年 | 22925篇 |
1969年 | 21493篇 |
1968年 | 19972篇 |
Objective: The objectives of the study were to assess the annualized relapse rate (ARR), socio-demographic and clinical characteristics, persistence and adherence rates, healthcare resource utilization and cost among patients with RMS who either switch to fingolimod or another FLIT in routine clinical practice.
Methods: A multicenter, observational, retrospective chart review was conducted across eight clinics in Canada between 1 May 2011 and 30 June 2013. The data was collected from two cohorts: patients who switched to fingolimod and patients who switched to FLIT from a previous FLIT.
Results and conclusions: A total of 124 patients were included in the study: 82 and 42 switched to fingolimod and FLIT, respectively. There were no significant differences in the patient characteristics at the date of switch except for number of previous disease-modifying therapies (DMTs) which was higher in the fingolimod cohort (fingolimod: 1.52; FLIT: 1.10, p?<?.001). The ARR during the first year of switching was numerically higher in the FLIT cohort compared to the fingolimod cohort (FLIT: 0.9 [95% CI 0.3–1.6]; fingolimod: 0.3 [95% CI 0.1–0.5]). The negative binomial model adjusted for the number of previous DMTs confirmed a statistically significant difference in ARR between the fingolimod and FLIT cohorts at 12?months of follow-up (p?=?.012). In the fingolimod cohort, 20.7% of patients experienced at least one relapse compared to 38.1% in the FLIT cohort. In both groups, a high proportion of patients (>90%) showed good treatment adherence (≥80% of prescribed doses). 相似文献
Methods: This retrospective, non-randomized, interventional comparative study included 38 eyes of 38 patients. All cases underwent PPV with silicone oil tamponade. The main outcome measure was improvement of final visual acuity relative to the presenting visual acuity and factors affecting the same Group A included eyes with favorable vision of 20/400 or better and Group B included the others.
Results: Group A included 16 eyes (42.10%), group B included 22 eyes (57.89%). In Group A 2 eyes out of 16 (12.5%) and in Group B 12 eyes out of 22 (54.54%) had RRD at presentation (p = 0.02, 95% CI for the difference 7.88–65.78%). The time interval between first presentation and development of RRD in Group A was 30.94 ± 38.8 days (median 30 days) whereas that in Group B was 10.81 ± 11.73 days (median 8 days) (p = 0.02). The odds of visual improvement post-vitrectomy when RRD occurred later was 8.4 (p = 0.01, 95% CI 1.53–46.1). The usage of systemic steroids (odds 5.2, p = 0.03, 95% CI 1.14–23.54) and oral valacyclovir (odds 4.33, p = 0.04, 95% CI 1.05–17.84) were associated with odds favoring a good visual outcome. Recurrent RRD was noted in 3/16 eyes (18.75%) in Group A and 13/22 eyes (59.09%) in Group B (p = 0.03).
Conclusion: Delayed occurrence of RRD after ARN is a good prognostic factor. Usage of systemic steroids and oral valacylocvir are associated with a favorable visual outcome when started before the onset of RRD. 相似文献